Annexon Inc (ANNX)

$3.21 +0.16 (5.25%)
Market Cap 352.74M
Revenue (ttm) 0.00
Net Income (ttm) -138.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,194,500
Avg Vol 1,931,868
Day's Range N/A - N/A
Shares Out 109.89M
Stochastic %K 71%
Beta 1.36
Analysts Strong Sell
Price Target $11.60

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 10:14 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $2.94 Contracts: $ANNX December 18, 2026 $3 Calls Scale in: $1.15- $1.40 Scale out: $1.78-$2.29 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Sly15
Sly15 Oct. 24 at 8:09 PM
$ANNX its better than bynd
0 · Reply
Acan1219
Acan1219 Oct. 24 at 5:57 PM
$ANNX Double Digits in coming my Bulls!!
0 · Reply
Tigerpicko
Tigerpicko Oct. 24 at 4:32 PM
$ANNX started towards $4
0 · Reply
BooEmmy
BooEmmy Oct. 24 at 3:31 PM
$ANNX Needs to break $3.40 for real momentum. If that happens shorts better watch out.
1 · Reply
ils85
ils85 Oct. 24 at 3:00 PM
$ANNX loading
1 · Reply
raj3406
raj3406 Oct. 22 at 4:10 PM
$ANNX Not surprised by today’s movement — looks like a good opportunity to buy some shares. It’ll likely rebound from here, with a small chance of retesting 2.80.
0 · Reply
xcapenstyle
xcapenstyle Oct. 21 at 11:36 PM
Anyone buying up $ANNX or $TELO ?
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 21 at 11:27 PM
$ANNX Why hasn’t this f’er released the news on the type c meeting…it was like 2 months ago
2 · Reply
Thomas105
Thomas105 Oct. 21 at 10:58 AM
$ANNX One positive aspect of the lack of news with an upward trend is that the peak is even higher when there is positive news. In this sense, hold
0 · Reply
Latest News on ANNX
Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:58 PM EDT - 6 weeks ago

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:38 AM EDT - 7 weeks ago

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Aug 18, 2025, 4:05 PM EDT - 2 months ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 14, 2025, 4:05 PM EDT - 2 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Aug 7, 2025, 4:30 PM EDT - 2 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 3 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jul 14, 2025, 12:47 PM EDT - 3 months ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Jun 18, 2025, 4:05 PM EDT - 4 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 5 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025, 4:05 PM EDT - 5 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025, 4:05 PM EDT - 5 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025, 8:00 AM EDT - 5 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025, 5:00 PM EDT - 6 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025, 8:00 AM EDT - 6 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 15, 2025, 7:12 AM EDT - 6 months ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 7 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 7 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 3, 2025, 8:00 AM EST - 8 months ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:05 PM EST - 8 months ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Feb 13, 2025, 8:30 AM EST - 9 months ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 10 months ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 16, 2024, 7:30 AM EST - 11 months ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 1 year ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Feb 21, 2024, 8:00 AM EST - 1 year ago

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Jan 7, 2024, 8:00 PM EST - 1 year ago

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 27, 2023, 6:30 AM EST - 1 year ago

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Annexon: ANX007 Advances Forward With Stellar Endpoint

Dec 23, 2023, 12:00 PM EST - 2 years ago

Annexon: ANX007 Advances Forward With Stellar Endpoint

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Dec 20, 2023, 5:27 PM EST - 2 years ago

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Dec 20, 2023, 5:10 PM EST - 2 years ago

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Dec 20, 2023, 5:08 PM EST - 2 years ago

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 22, 2023, 4:01 PM EST - 2 years ago

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 10:14 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $2.94 Contracts: $ANNX December 18, 2026 $3 Calls Scale in: $1.15- $1.40 Scale out: $1.78-$2.29 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Sly15
Sly15 Oct. 24 at 8:09 PM
$ANNX its better than bynd
0 · Reply
Acan1219
Acan1219 Oct. 24 at 5:57 PM
$ANNX Double Digits in coming my Bulls!!
0 · Reply
Tigerpicko
Tigerpicko Oct. 24 at 4:32 PM
$ANNX started towards $4
0 · Reply
BooEmmy
BooEmmy Oct. 24 at 3:31 PM
$ANNX Needs to break $3.40 for real momentum. If that happens shorts better watch out.
1 · Reply
ils85
ils85 Oct. 24 at 3:00 PM
$ANNX loading
1 · Reply
raj3406
raj3406 Oct. 22 at 4:10 PM
$ANNX Not surprised by today’s movement — looks like a good opportunity to buy some shares. It’ll likely rebound from here, with a small chance of retesting 2.80.
0 · Reply
xcapenstyle
xcapenstyle Oct. 21 at 11:36 PM
Anyone buying up $ANNX or $TELO ?
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 21 at 11:27 PM
$ANNX Why hasn’t this f’er released the news on the type c meeting…it was like 2 months ago
2 · Reply
Thomas105
Thomas105 Oct. 21 at 10:58 AM
$ANNX One positive aspect of the lack of news with an upward trend is that the peak is even higher when there is positive news. In this sense, hold
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 20 at 8:36 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $3.15 Contracts: $ANNX December 18, 2026 $4 Calls Scale in: $1.03- $1.26 Scale out: $1.61-$2.07 Can Easily Capture: 60% ROI Blended DTE: 425 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Acan1219
Acan1219 Oct. 20 at 4:37 PM
$ANNX Let’s Gooo my Bull’s!!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 11:18 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $3.17 Contracts: $ANNX December 18, 2026 $4 Calls Scale in: $1.17- $1.43 Scale out: $1.82-$2.34 Can Easily Capture: 60% ROI Blended DTE: 427 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Sly15
Sly15 Oct. 17 at 8:11 PM
$ANNX it seems like it has been getting pinned at the $3.00 strike price this week from options expiration today. Hopefully next week it can run.
0 · Reply
raj3406
raj3406 Oct. 17 at 3:34 PM
$ANNX Next Week might be a rough week for the market in general. I feel like we are headed for a Bumpy ride.
0 · Reply
CATatom
CATatom Oct. 17 at 2:07 PM
ADAP 0 shorts shares Watching: $BLMZ $GSIW $ANNX
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 17 at 4:53 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ANNX Current Share Price: $3.04 Contracts: $ANNX December 18, 2026 $4 Calls Scale in: $1.03- $1.26 Scale out: $1.61-$2.07 Can Easily Capture: 60% ROI Blended DTE: 428 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Tigerpicko
Tigerpicko Oct. 16 at 8:46 AM
$ANNX Presenting in Orlando AOO 2025 Annx portal and read under corporate October 2025 presentation will give you all the information and current progression For me this is ready to take off
3 · Reply
NewBee13
NewBee13 Oct. 16 at 1:08 AM
$ANNX Can we get a break out tomorrow? 3.40 maybe
2 · Reply
NewBee13
NewBee13 Oct. 15 at 6:10 PM
$ANNX Bizzarre price action today
0 · Reply
Consti22
Consti22 Oct. 14 at 2:52 PM
$ANNX
3 · Reply
Lightening_strikes
Lightening_strikes Oct. 13 at 2:18 PM
$ANNX down hard today why?
3 · Reply